VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ATOSAtossa Therapeutics, Inc.
$1.88$16M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksATOSRevenue History

ATOS logoAtossa Therapeutics, Inc. (ATOS) Revenue History

Annual and quarterly revenue from 2009 to present

TTM Revenue$0
YoY Growth—
Q1 2026$0
Revenue CAGR
3Y—
→
5Y—
→
10Y—
Best Fiscal Year$633K (2013)
Best Quarter$2.7M (Q2 2015)

ATOS Revenue Over Time (2009–2025)

ATOS Revenue Growth History

2 of 5 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2009—
2010—
2011—
2012+32022.8%
2013+31.3%
2014-93.7%
2015-95.6%
2016-100.0%
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—
2025—
FY2009 revenue growth
N/A
FY2010 revenue growth
N/A
FY2011 revenue growth
N/A
FY2012 revenue growth
+32022.8%
FY2013 revenue growth
+31.3%
FY2014 revenue growth
-93.7%
FY2015 revenue growth
-95.6%
FY2016 revenue growth
-100.0%
FY2017 revenue growth
N/A
FY2018 revenue growth
N/A
FY2019 revenue growth
N/A
FY2020 revenue growth
N/A
FY2021 revenue growth
N/A
FY2022 revenue growth
N/A
FY2023 revenue growth
N/A
FY2024 revenue growth
N/A
FY2025 revenue growth
N/A
DeclineStrong growth
Best: +32022.8% (FY2012)Worst: -100.0% (FY2016)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$0—
Q4 2025$0—
Q3 2025$0—
Q2 2025$0—
Q1 2025$0—
Q4 2024$0-100.0%
Q3 2024$0—
Q2 2024$0—
Seasonal Revenue Pattern (fiscal quarters)
Q1
21331%
Q2
30675%
Q3
8794%
Q4
-60700%

Multi-year avg. share of annual revenue by fiscal quarter

ATOS Revenue Analysis (2009–2025)

Current Revenue & Growth

As of June 28, 2026, Atossa Therapeutics, Inc. (ATOS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue

Historical Growth Trajectory

ATOS's historical revenue data shows various trends over time. Atossa Therapeutics, Inc.'s highest annual revenue of $632,558 was recorded in 2013.

Peer Comparison

Compared to Healthcare sector peers — including NKTR (-36.2% YoY), SNDX (+396.7% YoY), and TPVG. Compare ATOS vs NKTR →

ATOS Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
ATOS logoATOSCurrent$0---
NKTR logoNKTR$55M-36.2%-18.4%-236.8%
SNDX logoSNDX$172M+396.7%+157.7%-158.4%
TPVG logoTPVG$97M--77.9%
RCUS logoRCUS$247M+67.4%+25.9%-156.3%
AGEN logoAGEN$114M+24.5%+5.3%-18.0%
Best in groupLowest in group

ATOS Historical Revenue Data (2009–2025)

1–15 of 17 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$-37,141,000-
2024$0-$-17,000-$-27,621,000-
2023$0-$-23,000-$-31,377,000-
2022$0-$-8,000-$-27,691,000-
2021$0-$-23,000-$-20,521,000-
2020$0-$-46,600-$-14,607,000-
2019$0-$-52,789-$-17,265,425-
2018$0-$-44,197-$-11,434,233-
2017$0-$-128,994-$-7,187,456-
2016$0-100.0%$-303,482-$-7,249,620-
2015$2K-95.6%$-130,653-7431.9%$-12,758,618-725746.2%
2014$40K-93.7%$40K100.0%$-12,171,028-30323.0%
2013$633K+31.3%$137K21.7%$-10,784,643-1704.9%
2012$482K+32022.8%$416K86.4%$-5,069,030-1052.0%
2011$2K-$-95,690-6379.3%$-3,429,190-228612.7%
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

17+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ATOS — Frequently Asked Questions

Quick answers to the most common questions about buying ATOS stock.

Is ATOS's revenue growth accelerating or slowing?

ATOS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is ATOS's revenue history from 2009 to 2026?

Atossa Therapeutics, Inc. (ATOS) revenue history spans 2009 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is ATOS's long-term revenue growth rate (CAGR)?

Atossa Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ATOS.

Why does ATOS's quarterly revenue fluctuate?

ATOS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Atossa Therapeutics, Inc.'s revenue data from 2009 to 2026 shows full historical quarterly detail on this page.

How is ATOS's revenue distributed by segment?

ATOS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does ATOS's revenue compare to industry peers?

Atossa Therapeutics, Inc. (ATOS) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.